References

Methylation sequencing features a lower limit of detection (LoD) and improves ability to exclude clonal hematopoiesis noise.¹

Methylation-based detection identifies and quantifies tumor signals in early- and late-stage cancers with as low as 0.001% circulating tumor fraction (TF).¹

Methylation-based tumor fraction has superior sensitivity, enabling identification of tumor signal in 15%-50% more cancer patients.¹

QUANTIFY CANCER

Methylation
sequencing dramatically improves sensitivity
in cancer monitoring vs genomic signals alone.¹